TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28342534
Drug: Etanercept 50mg
Normalized name: ETANERCEPT 50MG/ML INJ SYRINGE
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50mg twice weekly
Study: 28342534
Drug: Ixekizumab 160mg
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab 160mg starting dose followed by 80mg Q2W
Study: 28342534
Drug: Ixekizumab 160mg
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab 160mg starting dose followed by 80mg Q4W
Study: 16378695
Drug: l-5-Hydroxytryptophan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-5-Hydroxytryptophan (200 mg)
Study: 16378695
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg) and l-5-Hydroxytryptophan (200 mg)
Study: 10877005
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg)
Study: 11012562
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once daily for 7 days
Study: 15729576
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin detemir
Study: 8818852
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/day orally once daily for 3 days
Study: 8818852
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg orally twice daily for 10 days
Study: 7078714
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose diazepam (150-200 mg/day)
Study: 7078714
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose diazepam (150-200 mg/day) with naloxone (30 mg i.v.)
Study: 16403108
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cream (placebo)
Study: 10449279
Drug: Twice-daily didanosine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily didanosine (ddI) plus twice-daily stavudine (d4T)
Study: 7605759
Drug: Alkalinized mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized mepivacaine (1 mL sodium bicarbonate per 10 mL mepivacaine)
Study: 20571433
Drug: paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: paroxetine 20 mg/d
Study: 17327187
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine gluconate surgical skin preparation (SP)
Study: 11865964
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg bosentan tablet (with food)
Study: 11865964
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of 62.5 mg bosentan (with food)
Study: 11865964
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of bosentan (without food)
Study: 7555159
Drug: Anistreplase (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase (30 U/5 min) + heparin
Study: 7555159
Drug: Heparin-only therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-only therapy
Study: 21519221
Drug: New dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dose regimen of artesunate and amodiaquine (NDRAA)
Study: 19650425
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (0.05-1.5 W/cm2, 1 MHz frequency, 3-9 minutes per session, 10 sessions total)
Study: 19650425
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (0.5-1.5 W/cm2, 4-9 minutes per session)
Study: 9814494
Drug: Propranolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol monotherapy after 7 days
Study: 7897129
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 10)
Study: 27785736
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin administered before a meal (30 min before a meal)
Study: 27785736
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin administered before sleep
Study: 27785736
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin administered during a meal
Study: 27785736
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin administered after a meal
Study: 25423326
Drug: Soy dietary
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy dietary supplement (90 mg of isoflavone)
Study: 21712835
Drug: Inulin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (24 g)
Study: 26178580
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (5000 IU) + Calcium (600 mg)
Study: 22015095
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg per day) in severe urticaria subgroup
Study: 10959805
Drug: 6 or
Normalized name: Serc-16 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or 9 million units (MU) interferon three times a week for 6 months (total dose: 468 or 702 MU)
Study: 10959805
Drug: 6MU of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MU of IFN over 6 months (total dose 564 MU)
Study: 8622389
Drug: Bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200 mg three times daily)
Study: 8169401
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg every 8 h) and fluconazole (400 mg daily) for 7 days
Study: 2467134
Drug: Amlodipine 2.5-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5-10.0 mg daily
Study: 27442085
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 1.2% Atorvastatin (ATV)
Study: 25706516
Drug: AOK-proReha treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOK-proReha treatment approach
Study: 24717954
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day for 90 days)
Study: 18596271
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 mg of epinephrine and 40 IU of vasopressin
Study: 9878938
Drug: Dalteparin 120
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 120 IU/kg body weight twice daily
Study: 9878938
Drug: Dalteparin 7500
Normalized name: dalteparin 7500 intl units/0.3 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 7500 IU once daily (fixed dose)
Study: 9878938
Drug: Weight-adjusted treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted treatment
Study: 9878938
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose treatment
Study: 31499373
Drug: Acute phase
Normalized name: Acute phase reactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute phase treatment
Study: 9878938
Drug: Fixed-dose treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose treatment
Study: 4012191
Drug: Flunarizine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (15 mg nocte)
Study: 26768928
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (control) administered in a similar manner to Dex
Study: 29961346
Drug: Client-centred activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centred activities of daily living (CADL) intervention
Study: 22678673
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of akatinol memantine 20 mg in the morning
Study: 16383037
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 150 mg diammonium glycyrrhizinate per day for 14 days (T group)
Study: 20104197
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (C group)
Study: 7593517
Drug: Nafarelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (200 micrograms twice daily as a nasal spray)
Study: 3833371
Drug: Liquid capsules
Normalized name: Calcium Liquid Capsules with Vitamin D
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid capsules
Study: 29521723
Drug: Mechanical Lithotripsy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical Lithotripsy (ML)
Study: 26885787
Drug: Dapsone 5%
Normalized name: DAPSONE 5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 5% gel (twice daily) with oral doxycycline hyclate 100mg (once daily) for 12 weeks, followed by dapsone 5% gel (twice daily) for 12 weeks
Study: 12012079
Drug: Bicarbonate supplement
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate supplement
Study: 10078718
Drug: Oxcarbazepine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 1,200 mg twice daily
Study: 2154855
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus etoposide (cisplatin 120 mg/m2, etoposide 100 mg/m2, days 1 to 3)
Study: 389813
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP)
Study: 28855224
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acid preparation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Study: 11306214
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment interventions
Study: 7957502
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with DDAVP
Study: 7957502
Drug: Endonasal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endonasal treatment with DDAVP
Study: 3661642
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nadolol twice daily
Study: 3661642
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nadolol twice daily
Study: 31490858
Drug: Chemotherapy-periodized exercise
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-periodized exercise prescription
Study: 31490858
Drug: Standard linear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard linear exercise prescription
Study: 8638788
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 50 micrograms
Study: 8638788
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100 micrograms
Study: 8638788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 50 micrograms morphine + 50 micrograms neostigmine
Study: 1538160
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin with loperamide
Study: 1538160
Drug: 3-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day course of 500 mg ciprofloxacin twice daily with loperamide
Study: 1538160
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin with placebo
Study: 23018219
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or gonadotropin-releasing hormone agonist
Study: 17205530
Drug: Non-aspirin NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin NSAIDs (prescription for at least 1 year)
Study: 7486110
Drug: 3% modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% modified fluid gelatin (GEL)
Study: 10068848
Drug: Aprindine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprindine (60 mg daily)
Study: 1903497
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg b.i.d. (increased to 40 mg per day after 8 weeks)
Study: 1903497
Drug: Cholestyramine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 8 g b.i.d. (added after 16 weeks)
Study: 1903497
Drug: Gemfibrocil 900
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrocil 900 mg (two thirds of cholestyramine group switched)
Study: 7342466
Drug: Allyloestrenol (Gestanon)
Normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allyloestrenol (Gestanon) 10 mg daily until the 8th week, then 15 to 20 mg daily until the 12th week, then tapered off
Study: 7342466
Drug: Allyloestrenol (Gestanon)
Normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allyloestrenol (Gestanon) administered immediately after ovulation
Study: 7342466
Drug: Allyloestrenol (Gestanon)
Normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allyloestrenol (Gestanon) administered after the first missed period
Study: 19576120
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg, 3/d)
Study: 19576120
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg, 3/d)
Study: 17895886
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5‐fluorouracil (5‐FU) and leucovorin (LV)
Study: 17895886
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5‐FU and LV
Study: 11588893
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E intake from supplements
Study: 11164130
Drug: Age, income,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, income, hormone use, and geographic location
Study: 9581724
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg twice daily) for 6 months
Study: 8043664
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) insulin administration
Study: 48727
Drug: Dexamethasone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (16 mg. per 24 hours for 6 days)
Study: 23759410
Drug: Website, monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website, monthly group sessions, and follow-up calls (WG)
Study: 21486975
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing schedule (0, 2, and 6 months)
Study: 21486975
Drug: Alternative dosing
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative dosing schedule (0, 3, and 9 months)
Study: 21486975
Drug: Alternative dosing
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative dosing schedule (0, 6, and 12 months)
Study: 21486975
Drug: Alternative dosing
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative dosing schedule (0, 12, and 24 months)
Study: 10955199
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microsphere, 0.1%
Study: 23022285
Drug: 6-month pioglitazone
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month pioglitazone treatment
Study: 10897370
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg)
Study: 9413087
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell rabies vaccine
Study: 9413087
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell rabies vaccine and human rabies immune globulin
Study: 9413087
Drug: Chick embryo
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chick embryo vaccine without immune globulin
Study: 8405014
Drug: 0.150 mg
Normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg desogestrel + 0.500 mg 17 beta‐oestradiol cyclo‐octyl acetate
Study: 8405014
Drug: 0.150 mg
Normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg desogestrel + 1.0 mg 17 beta‐oestradiol decanoate
Study: 2939221
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous ketanserin (0.15 mg/kg)
Study: 2939221
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral ketanserin (40 mg)
Study: 2939221
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral ketanserin (40 mg once-daily)
Study: 29940055
Drug: Single-shot adductor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot adductor canal block (SS-ACB) with 20 mL of 0.5% ropivacaine preoperatively and saline boluses at 12 and 24 hours postoperatively
Study: 29940055
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal block (C-ACB) with 20 mL of 0.5% ropivacaine preoperatively and at 12 and 24 hours postoperatively
Study: 19758373
Drug: Anti-helminthic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-helminthic therapy
Study: 9471022
Drug: IFN‐alpha at
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha at a dosage of 2‐4 mega units/square metre of body surface area thrice weekly for 6‐12 months
Study: 9471022
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage and longer treatment duration of IFN‐alpha for patients infected with HCV genotype 1b
Study: 7525125
Drug: Casodex 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 150 mg daily
Study: 31769377
Drug: Trial-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial-based cognitive therapy (TBCT)
Study: 31793418
Drug: Topical Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cannabidiol Oil (250 mg CBD/3 fl. oz)
Study: 26524798
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (1 mg s.c. injection three days after embryo transfer)
Study: 21323540
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (0.625 mg in 0.025 ml of solution)
Study: 17997442
Drug: Parenteral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral estrogen (polyestradiol phosphate)
Study: 27618916
Drug: Zhengtian Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhengtian Capsule
Study: 23059435
Drug: Acupuncture (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (30 min twice a week for 5 weeks)
Study: 8787366
Drug: Artemether (intramuscular,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (intramuscular, given for 5 days)
Study: 8787366
Drug: Mefloquine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (single oral dose, 25 mg/kg/body-weight)
Study: 6391154
Drug: 80-g vegetable-protein-supplemented
Normalized name: VEGETABLE CARBON
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-g vegetable-protein-supplemented diet (30 g animal and 50 g vegetable, diet B)
Study: 6391154
Drug: 40-g protein
Normalized name: soy protein isolate 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g protein diet (30 g animal and 10 g vegetable, diet A)
Study: 30318624
Drug: TAC-QD (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-QD (once-daily tacrolimus)
Study: 30318624
Drug: TAC-BID (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-BID (twice-daily tacrolimus)
Study: 26459175
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy (PEXG) without metformin
Study: 21876066
Drug: Adjunctive levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive levetiracetam (20-100 mg/kg/d, mean 50.2 mg/kg/d)
Study: 18314112
Drug: Early CC
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early CC group (100 mg of clomiphene citrate daily starting after medroxyprogesterone acetate for 5 days)
Study: 18314112
Drug: Late CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late CC group (100 mg of clomiphene citrate daily starting on day 3 of menses for 5 days)
Study: 18314112
Drug: Late CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late CC group
Study: 9840608
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine administered at 10 and 14 weeks
Study: 9840608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (meningococcal A/C polysaccharide vaccine)
Study: 9840608
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine (group 2)
Study: 9840608
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine (both groups)
Study: 7863249
Drug: Nizatidine 20
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine 20 mg/h